Resources

70 Resources for

drug

  • Subscribe to this listing via:
  • RSS
  • Email

BNET Resources

Performance-Enhancing Drugs at Work: An Ethics Poll
Is the asterisk coming to the business world? The use of performance-enhancing drugs has clogged up the sports world for the last couple of years, but steroid and human growth hormone are not the only way to get a chemical advantage. What about the brain drugs, those...
Tags: Human Resources, William Baker, Leadership, Management, Performance Management, Business Ethics, Ethics, Drug, Performance, Workforce Management
Blog posts 2008-05-12
Marketing Trumps Science in Vytorin Scandal
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
Tags: Online Communications, Marketing, E-mail, Marketing Research, Schering, Zetia, Vytorin, Drug, Merck & Co. Inc., David P. Hamilton
Blog posts 2008-04-01
Brain Steroids: Ban Or Boost?
Drugs are bad for productivity, right? Well, maybe not. While you can probably correlate productivity increases with declines in per capita drinking, what about coffee or Diet Coke? These can act as mild stimulants. Then there's full-fledged brain steroids, say, a drug like Provigil, which...
Tags: Richard Posner, Drug, Drugs, Blogging, Benefits, Internet, Human Resources, Michael Fitzgerald
Blog posts 2008-03-24
Landmark Ruling On Drug Cases
In the wake of a recent lawsuit involving the drug company Wyeth, the Supreme Court has ruled that the FDA is not exclusively responsible for the safety of prescription drugs. Wyatt Andrews reports.
Tags: MoneyWatch, Federal Government, Healthcare, Government, Evening, Drug, Prescription, Medicine, Pill, Health, Law, Legal, Justice, Federal
Videos 2009-04-15
Better Management through Drug Abuse
In the future, corporate drug testing will be to see if you're taking the drugs the company wants you to take. An argument found and posted by Nick Carr, in Managing productivity through pharmacology, holds that people should be allowed to take drugs that dull their minds...
Tags: Nick Carr, Drug, Frank Pasquale, Policies And Procedures, Government, Human Resources, Michael Fitzgerald
Blog posts 2009-01-06
List of 56 Drugs That Should Not Be Mixed With Viagra Contains Some Surprises
Public Citizen has published a list of 56 drugs that interact badly with erectile dysfunction pills such as Pfizer's Viagra. Public Citizen's WorstPills.com site reports: In combination with ED drugs, these 56 drugs can cause dangerous falls in blood pressure that could lead to a heart attack or stroke;...
Tags: Blood Pressure, Pfizer Inc., Drug, Viagra, Healthcare, Jim Edwards
Blog posts 2009-01-06
Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration
A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...
Tags: FDA, Vaccine, Administration, Drug Company, U.S. Congress, Pharmaceutical Company, Health Care, Drug, Teva, Biotech Drug, Biotechnology, Healthcare, Vertical Industries, Benefits, Enterprise Software, Software, Human Resources, Jim Edwards
Blog posts 2008-12-31
Popping Productivity in a Pill
Is it ethical to take memory-enhancing drugs or stimulants to boost your productivity and performance at work? And even if it is, would you be willing to risk potential health consequences to get ahead? Those are key questions surrounding the debate about "brain doping,"...
Tags: Health Care, Drug, Vertical Industries, Benefits, Healthcare, Strategy, Enterprise Software, Software, Human Resources, Management, CC Holland
Blog posts 2008-12-11
BMJ: PDUFA, Speedy Marketing Spread Risks of New Drugs
The faster a drug is approved the more likely it is to be withdrawn or have safety warnings added later, according to the author of a study in the British Medical Journal. In addition, the rapid rollout of mass marketing plans increases the risk that large numbers of patients will...
Tags: Patient, Merck & Co. Inc., Drug, Marketing Research, Marketing, Jim Edwards
Blog posts 2008-12-08
The U.K.'s NICE: A Model for the U.S.?
The New York Times has aired another episode of its "Evidence Gap" series, and it's infuriating. This one is about the National Institute for Health and Clinical Excellence, the U.K.'s price-approval body for National Health Service drugs. The purpose of NICE is to evaluate drug efficacy and...
Tags: Patient, Health Care, Celgene Corp., Drug, NICE, Bruce Hardy, Benefits, Vertical Industries, Healthcare, Human Resources, Enterprise Software, Software, Jim Edwards
Blog posts 2008-12-03
Our Favorite Drug Company Conference Call Tap Dancers
Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
Tags: Revenue, Operating Margin, Patient, Drug, CEO, Vyvanse, Operational Accounting, Finance, Jim Edwards
Blog posts 2008-11-13
Pharma Roundup: Sanofi in China, Wyeth and Fen-Phen, Chantix Problems, and More
Special "While Merck Was Slashing Jobs" Edition: Sanofi-Aventis boosts R&D program in China, Wyeth still paying for Fen-Phen, Chantix blamed for 1,001 Q1 injuries, one in four biotech drugs cause dangerous side effects. by John Maas
Tags: China, Wyeth, Research & Development, Biotechnology, Business Operations, John Maas, Drug, Biometrics, Authentication/Encryption, Security
Blog posts 2008-10-22
Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s Critics
It's been a just a day since Dendreon announced that the interim analysis of its Provenge anti-prostate cancer candidate showed some -- but not enough -- improvement in sufferers, and already the drug's army of web activists is heaping abuse on those who suggest that possibly, just possibly, this drug...
Tags: FDA, Analysis, Drug, Dendreon, Provenge, Federal Government, Government, Jim Edwards
Blog posts 2008-10-07
BNET Focus on Antidepressants: Part 2, Controversies
While the antidepressant market is both robust and lucrative, as we saw in part 1 of this three-part series, it is also controversial. No drug category is so dogged by doubts and questions, and yet so widely prescribed, as antidepressants. The most recent major event in the...
Tags: FDA, Drug Company, Suicide, Drug, Comments Section, Senate Finance Committee, Federal Government, Government, Jim Edwards
Blog posts 2008-10-01
A Lilly-ImClone Deal May Offer the Drama that CEO Lechleiter Craves
Today came the news that Eli Lilly is one of the mystery suitors in the ImClone deal that Bristol-Myers Squibb was just booted from. If CEO John Lechleiter were to scoop up ImClone -- thus bolting on the cancer specialist's pipeline to replace the absence of its...
Tags: Drug, John Lechleiter, Lilly, Zyprexa, Zyprexa New, Federal Government, Workforce Management, Government, Human Resources, Jim Edwards
Blog posts 2008-09-29
Shire's Big Gamble on ADHD Drug Vyvanse
One of the recent unheralded successes of the drug world was Shire Pharmaceuticals' launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive --...
Tags: Revenue, Generic, Drug, Shire, Vyvanse, Sanofi, Operational Accounting, Finance, Jim Edwards
Blog posts 2008-09-04
Behind the Byetta Crisis: Is This Drug Really All That and a Bag of (Fat-Free) Chips?
The current big headache for Eli Lilly and Amylin is their diabetes drug Byetta, which the FDA has linked to six cases of fatal pancreatitis. The two companies, which jointly market the drug, held a conference call yesterday in which they hoped to calm nervous investors. (It...
Tags: Patient, Drug, Chip, Byetta, Lilly, Nausea, Americans With Disabilities Act (ADA), Federal Government, Corporate Governance, Human Resources, Gender And Diversity, Government, Business Operations, Corporate Law, Jim Edwards
Blog posts 2008-08-28
GSK Signs Wynonna Judd to Endorse Alli, Its Flagging Weight Loss Drug
GlaxoSmithKline is not giving up on Alli, its OTC weight-loss pill that has seen only modest sales. The company announced it will begin a campaign featuring singer Wynonna Judd. Check out the Alli/Judd web site here. Alli made only $88 million in sales for the first nine...
Tags: Drug, GSK, Alli, Sales Strategy, Vertical Industries, Benefits, Healthcare, Federal Government, Sales Force Management, Marketing Research, Sales, Enterprise Software, Software, Human Resources, Government, Marketing, Jim Edwards
Blog posts 2009-01-07
Would You Take Drugs to Boost Your Productivity? A Pill-Popping Poll
In Better Management Through Drug Abuse, I raise the specter of top management requiring people to take certain kinds of mind-altering drugs. The arguments in favor of using such drugs, as put forth by academics, seem absurdly weak to me. And yet there are clear reasons to consider such drugs,...
Tags: Drug, Performance Management, Human Resources, Workforce Management, Michael Fitzgerald
Blog posts 2009-01-09
Nine New Drugs for China Sky One
ChinaBio Today submits: China Sky One Medical, Inc. CSKI has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million). The company estimates the nine products will generate $5 million in revenue during 2009. According to China...
Tags: China, Drug, Seeking Alpha, ChinaBio Today, Operational Accounting, Finance, China Sky One Medical Inc.
External links 2008-11-13
advertisement
advertisement
Click Here